黄芩素的研发进展及其临床药理学

doi:10.12092/j.issn.1009-2501.2020.06.013

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (6): 701-708.doi: 10.12092/j.issn.1009-2501.2020.06.013

黄芩素的研发进展及其临床药理学

单慧¹, 杜胤骁², 白鹤群¹, 陈军霞¹, 赫晓林¹, 王倩¹, 胡子鉴¹, 吕承¹, 陈小平^2,3,4

¹石药集团中奇制药技术(石家庄)有限公司,临床开发事业部,上海 200040;
²中南大学湘雅医院临床药理研究所,长沙 410008,湖南;
³中南大学临床药理研究所,长沙 410078,湖南;
⁴国家老年疾病临床医学研究中心(湘雅),长沙 410078,湖南

收稿日期:2020-05-11 出版日期:2020-06-26 发布日期:2020-07-09
通讯作者: 陈小平,女,博士生导师,研究方向:临床药理学、药物基因组学与个体化医学。Tel: 0731-84805380 E-mail: chenxiaoping@csu.edu.cn
作者简介:单慧,女,硕士,研究方向:转化医学、临床药理学。Tel:021-69673912 E-mail:shanhui@mail.ecspc.com
基金资助:
科技部重大新药创制资助(2013ZX09509107)

Progress in the development of baicalein and its clinical pharmacology study

SHAN Hui¹, DU Yinxiao², BAI Hequn¹, CHEN Junxia¹, HE Xiaolin¹, WANG Qian¹, HU Zijian¹, LV Cheng¹, CHEN Xiaoping^2,3,4

¹ CSPC Zhongqi Pharmaceutical Technology (shijiazhuang) Company,Clinical Development Division, Shanghai 200040, China;
² Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China;
³ Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410008, Hunan, China;
⁴ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China

Received:2020-05-11 Online:2020-06-26 Published:2020-07-09

摘要/Abstract

摘要： 由新型冠状病毒(SARS-Cov-2)所致的新型冠状病毒肺炎(COVID-19)疫情严峻,目前尚缺乏特效抗病毒药物。中医药在新冠肺炎治疗中起到举足轻重的作用,黄芩是国家卫生健康委员会新型冠状病毒肺炎诊疗方案推荐的清肺排毒汤以及武汉协和2号方和3号方的重要组成部分。黄芩素是黄芩的主要药效物质基础,具有抗病毒、抗菌、抗过敏、免疫调节等多种药理作用,具有广阔的开发前景。本文就黄芩素的临床前和临床研究、潜在的药物相互作用等方面的进展进行了系统综述,为黄芩素的进一步开发和临床应用奠定基础。

关键词: 黄芩素, 抗病毒, 免疫调节, 临床药理

Abstract: The 2019 new coronavirus pneumonia (COVID-19) caused by the new coronavirus (SARS-Cov-2) infection has become a global pandemic, and currently there is a lack of specific antiviral drugs. Traditional Chinese medicine plays a critical role in the treatment of COVID-19. Scutellaria baicalensis is an important component of the Qingfei Paidu decoction recommended in the Chinese National Health Commission's Treatment Regimen and Wuhan Xiehe No.2 and No.3 prescriptions as well. Baicalein is the main ingredient in Scutellaria baicalensis, and has various pharmacological effects such as antiviral, antibacterial, antiallergic, and immunomodulatory activities, showing a broad prospect in new drug development. This article systemically reviewed the recent progress in the preclinical and clinical studies, potential drug interactions, and other aspects of baicalein, which will help further development and clinical application of the drug.

Key words: baicalein, antivirus, immunomodulation, clinical pharmacology

中图分类号:

R285

单慧, 杜胤骁, 白鹤群, 陈军霞, 赫晓林, 王倩, 胡子鉴, 吕承, 陈小平. 黄芩素的研发进展及其临床药理学[J]. 中国临床药理学与治疗学, 2020, 25(6): 701-708.

SHAN Hui, DU Yinxiao, BAI Hequn, CHEN Junxia, HE Xiaolin, WANG Qian, HU Zijian, LV Cheng, CHEN Xiaoping. Progress in the development of baicalein and its clinical pharmacology study[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 701-708.

参考文献 48

[1]	Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges [J]. Int J Antimicrob Agents, 2020, 55(3): 105924.
[2]	Srinivas NR. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives [J]. Xenobiotica; the fate of foreign compounds in biological systems, 2010, 40(5): 357-367.
[3]	张海丽, 游雷鸣, 刘慧, 等. 汉黄芩素对LPS和ATP联合诱导的巨噬细胞炎症反应的抑制作用 [J]. 中国免疫学杂志, 2019, 35(9): 1059-1063.
[4]	张春辉, 邢雪琨, 张慧. 黄芩的药理作用研究 [J]. 中兽医医药杂志, 2020, 39(2): 98-100.
[5]	辛文妤, 宋俊科, 何国荣, 等. 黄芩素和黄芩苷的药理作用及机制研究进展 [J]. 中国新药杂志, 2013, 22(6): 647-653, 659.
[6]	王赫然, 王茜. 新型冠状病毒有关药物和生物制品研究进展 [J]. 药学学报, 2020, 55(3): 349-354.
[7]	Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds [J]. J Clin Virol, 2004, 31(1): 69-75.
[8]	Hour MJ, Huang SH, Chang CY, et al. Baicalein, ethyl acetate, and chloroform extracts of scutellaria baicalensis inhibit the neuraminidase activity of pandemic 2009 H1N1 and seasonal influenza a viruses [J]. Evid Based Complement Alternat Med, 2013, 2013: 750803.
[9]	Ahn HC, Lee SY, Kim JW, et al. Binding aspects of baicalein to HIV-1 integrase [J]. Mol Cells, 2001, 12(1): 127-130.
[10]	Michaelis M, Sithisarn P, Cinatl J Jr. Effects of flavonoid-induced oxidative stress on anti-H5N1 influenza a virus activity exerted by baicalein and biochanin A [J]. BMC Research Notes, 2014, 7: 384.
[11]	Johari J, Kianmehr A, Mustafa MR, et al. Antiviral activity of baicalein and quercetin against the Japanese encephalitis virus [J]. Int J Mol Sci, 2012, 13(12): 16785-16795.
[12]	Oo A, Teoh BT, Sam SS, et al. Baicalein and baicalin as Zika virus inhibitors [J]. Arch Virol, 2019, 164(2): 585-593.
[13]	Liu Y, Yao W, Si L, et al. Chinese herbal extract Su-duxing had potent inhibitory effects on both wild-type and entecavir-resistant hepatitis B virus (HBV) in vitro and effectively suppressed HBV replication in mouse model [J]. Antiviral Res, 2018, 155: 39-47.
[14]	Keum YS. Inhibition of SARS coronavirus helicase by baicalein [J]. Soc, 2013, 34(11): 3187-3188.
[15]	Moghaddam E, Teoh BT, Sam SS, et al. Baicalin, a metabolite of baicalein with antiviral activity against dengue virus [J]. Sci Rep, 2014, 4: 5452.
[16]	吴莹, 金叶智, 吴珺, 等. 黄芩主要成分体外抗甲型流感病毒作用的研究 [J]. 北京中医药大学学报, 2010, 33(8): 541-545.
[17]	Zhi HJ, Zhu HY, Zhang YY, et al. In vivo effect of quantified flavonoids-enriched extract of Scutellaria baicalensis root on acute lung injury induced by influenza A virus [J]. Phytomedicine, 2019, 57: 105-116.
[18]	Xu G, Dou J, Zhang L, et al. Inhibitory effects of baicalein on the influenza virus in vivo is determined by baicalin in the serum [J]. Biolog Pharmaceu Bull, 2010, 33(2): 238-243.
[19]	Chen L, Dou J, Su Z, et al. Synergistic activity of baicalein with ribavirin against influenza A (H1N1) virus infections in cell culture and in mice [J]. Antiviral Res, 2011, 91(3): 314-320.
[20]	Pu WL, Bai RY, Zhou K, et al. Baicalein attenuates pancreatic inflammatory injury through regulating MAPK, STAT 3 and NF-κB activation [J]. Int Immunopharmacol, 2019, 72: 204-210.
[21]	Jang H, Lee J, Park S, et al. Baicalein mitigates radiation-induced enteritis by improving endothelial dysfunction [J]. Front Pharmacol, 2019, 10: 892.
[22]	王雷, 杨新建, 范玉强. 黄芩素滴丸对大鼠的急性毒性实验研究 [J]. 中国药房, 2013, 24(15): 1356-1359.
[23]	张喜平, 程琪辉, 陈君峰, 等. 黄芩素胶囊的小鼠急性毒性实验 [J]. 医学研究杂志, 2007, 36(4): 52-55.
[24]	沈安, 吴璐, 朱卫丰. 黄芩中黄芩苷与黄芩素的体内外转化研究进展[J]. 江西中医药, 2017, 48(9): 71-74.
[25]	Liu TM, Jiang XH. Investigation of the absorption mechanisms of baicalin and baicalein in rats [J]. J Pharm Sci, 2006, 95(6): 1326-1333.
[26]	Li W, Pi J, Zhang Y, et al. A strategy to improve the oral availability of baicalein: The baicalein-theophylline cocrystal [J]. Fitoterapia, 2018, 129: 85-93.
[27]	赵振宇, 董武军, 刘玉玲. 黄芩素在小鼠体内的药动学及其组织分布研究 [J]. 中国医药工业杂志, 2009, 40(9): 687-690.
[28]	Jia ZY, Bai ZZ, Jiang LJ, et al. Ocular pharmacokinetic study on baicalin in lens of rabbits following intragastric administration [J]. Graefes Arch Clin Exp Ophthalmol, 2010, 248(1): 59-63.
[29]	Tang Y, Zhu H, Zhang Y, et al. Determination of human plasma protein binding of baicalin by ultrafiltration and high-performance liquid chromatography [J]. Biomed Chromatogr, 2006, 20(10): 1116-1119.
[30]	Tian S, He G, Song J, et al. Pharmacokinetic study of baicalein after oral administration in monkeys [J]. Fitoterapia, 2012, 83(3): 532-540.
[31]	Xu P, Zhou H, Li YZ, et al. Baicalein enhances the oral bioavailability and hepatoprotective effects of silybin through the inhibition of efflux transporters BCRP and MRP2 [J]. Front Pharmacol, 2018, 9: 1115.
[32]	Xing J, Chen X, Zhong D. Absorption and enterohepatic circulation of baicalin in rats[J]. Life sciences, 2005, 78(2): 140-146.
[33]	Zhang L, Lin G, Zuo Z. Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein [J]. Pharmaceu Res, 2007, 24(1): 81-89.
[34]	柳文媛, 徐维露, 李萍, 等. LC-MS/MS法研究黄芩素及其主要代谢物在大鼠体内的组织分布与排泄 [J]. 中国药科大学学报, 2009, 40(4): 348-352.
[35]	Li M, Shi A, Pang H, et al. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects [J]. J Ethnopharmacol, 2014, 156: 210-215.
[36]	Pang H, Xue W, Shi A, et al. Multiple-ascending-dose pharmacokinetics and safety evaluation of baicalein chewable tablets in healthy Chinese volunteers [J]. Clin Drug Invest, 2016, 36(9): 713-724.
[37]	Fan L, Wang JC, Jiang F, et al. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation [J]. Eur J Clin Pharmacol, 2009, 65(4): 403-409.
[38]	Fan L, Wang G, Wang LS, et al. Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole [J]. Acta Pharmacol Sin, 2007, 28(10): 1685-1692.
[39]	Jang SI, Kim HJ, Hwang KM, et al. Hepatoprotective effect of baicalin, a major flavone from Scutellaria radix, on acetaminophen-induced liver injury in mice [J]. Immunopharmacol Immunotoxicol, 2003, 25(4): 585-594.
[40]	Yue J, Peng R, Chen J, et al. Effects of rifampin on CYP2E1-dependent hepatotoxicity of isoniazid in rats [J]. Pharmacol Res, 2009, 59(2): 112-119.
[41]	Tsai PL,Tsai TH. Pharmacokinetics of baicalin in rats and its interactions with cyclosporin A, quinidine and SKF-525A: a microdialysis study [J]. Planta Med, 2004, 70(11): 1069-1074.
[42]	Fan L, Zhang W, Guo D, et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1 [J]. Clin Pharmacol Ther, 2008, 83(3): 471-476.
[43]	Itoh T, Itagaki S, Sumi Y, et al. Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2 [J]. Cancer Chemother Pharmacol, 2005, 55(5): 420-424.
[44]	Kalapos-Kovács B, Juhász V, Temesszentandrási-Ambrus C, et al. Baicalin is a substrate of OATP2B1 and OATP1B3 [J]. Phytother Res, 2018, 32(8): 1647-1650.
[45]	杨艳秋, 刘贵军, 熊丽辉. 黄芩的主要成分对Caco-2细胞P-gp表达的影响 [J]. 中药材, 2016, 39(9): 2122-2125.
[46]	Akao T, Kawabata K, Yanagisawa E, et al. Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form [J]. J Pharmacy Pharmacol, 2000, 52(12): 1563-1568.
[47]	张佳丽, 基于CYP3A和P-gp的黄芩苷药物相互作用研究 [D]. 郑州大学, 2019.
[48]	黄凯, 刘志浩, 贺晴. 黄芩苷对大鼠和人肝微粒体CYP450酶的抑制作用 [J]. 中国实验方剂学杂志, 2016, 22(3): 20-23.

黄芩素的研发进展及其临床药理学

Progress in the development of baicalein and its clinical pharmacology study

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 48

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王剑, 孙永东, 周兴玮, 刘雷, 陈龙, 童兴科, 朱佳丽. 黄芩素经由miR-125b-5p/IRF4轴进而促进喉癌细胞死亡并抑制其侵袭的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1209-1218.
[2]	高丽丽, 王玉珠, 王燕, 李健, 王骏. 抗肿瘤抗体偶联药物临床药理学研究的若干问题与考虑[J]. 中国临床药理学与治疗学, 2023, 28(1): 75-85.
[3]	邓颖, 白殊同. 金圣草黄素相关药理作用机制的研究进展 [J]. 中国临床药理学与治疗学, 2022, 27(10): 1155-1162.
[4]	彭静, 宋静, 栾家杰. 新型冠状病毒肺炎治疗新策略：间充质干细胞疗法[J]. 中国临床药理学与治疗学, 2021, 26(9): 1073-1079.
[5]	章权, 石仕元, 韩贵和. 1,25二羟维生素D3在脊柱结核治疗中的免疫调节作用[J]. 中国临床药理学与治疗学, 2021, 26(7): 787-793.
[6]	张露, 林良沫, 刘可可, 黄娅敏, 黄行行, 杨永榆, 肖坚. 新型冠状病毒肺炎抗病毒药物的治疗药物监测及药代动力学研究进展[J]. 中国临床药理学与治疗学, 2020, 25(5): 566-575.
[7]	蓝巧帅，夏帅，周洁，王茜，陆路. 新型冠状病毒SARS-CoV-2感染治疗中的“老药新用”[J]. 中国临床药理学与治疗学, 2020, 25(2): 126-134.
[8]	常香香，韦中玲，郑幸媛，李慧敏，黄来全. 多发性骨髓瘤的治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 107-116.
[9]	吴姗姗，唐余燕，陈小华，张毅，王洁玲，汤正好，臧国庆，余永胜. CTP-HBcAg_18-27-Tapasin联合佐剂CpG ODN免疫转基因小鼠的免疫应答研究[J]. 中国临床药理学与治疗学, 2018, 23(3): 271-276.
[10]	杨迪，袁婷婷，干舒蕾，崔亚娇，丁茹，吴玉林，杨劲. 静脉注射黄芩苷、黄芩素在大鼠体内的药代规律比较研究[J]. 中国临床药理学与治疗学, 2017, 22(4): 394-400.
[11]	张佩红，陈啸洪，陈冰蓉，李华浚. 哮喘儿童血清细胞因子水平及布拉氏酵母菌干预的研究[J]. 中国临床药理学与治疗学, 2017, 22(3): 332-336.
[12]	王玉珠, 萧惠来. FDA儿科临床药理学研究指导原则简介[J]. 中国临床药理学与治疗学, 2015, 20(8): 841-848.
[13]	王立凤, 张志宇, 李真真, 梁映霞. 静脉注射免疫球蛋白对神经病理性疼痛治疗作用的研究进展[J]. 中国临床药理学与治疗学, 2015, 20(2): 213-216.
[14]	吕亚囡, 董群. 大蒜素对不同年龄组小鼠血清神经递质5-羟色胺和β-内啡肽的影响[J]. 中国临床药理学与治疗学, 2012, 17(8): 884-887.
[15]	毛捷, 盛莉莉, 徐善水, 王宣之. 黄芩素对星形细胞瘤SHG-44细胞增殖、侵袭迁移的影响[J]. 中国临床药理学与治疗学, 2012, 17(7): 750-754.